CRISPR Therapeutics Stock Price - CRSP

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
CRISPR Therapeutics AG CRSP NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.08 0.14% 58.41 59.40 57.30 58.43 58.33 14:38:01
Bid Price Ask Price Spread Spread % News
58.40 58.44 0.04 0.07% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
8,394 860,061 $ 58.27 $ 50,117,755 1,092,389 29.3401 - 74.48
Last Trade Time Type Quantity Stock Price Currency
14:37:44 100 $ 58.41 USD

CRISPR Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 3.28B 56.19M $ -164.98M -3.44 6,151.47 55.34M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

CRISPR Therapeutics News

Loading Messages....

Latest CRSP Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CRSP Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week58.7961.1757.3059.24941,864-0.38-0.65%
1 Month67.6268.5457.0061.131,110,032-9.21-13.62%
3 Months45.0074.4844.8062.491,231,19513.4129.8%
6 Months49.1674.4835.4656.54827,5149.2518.82%
1 Year33.9674.4829.340149.08729,60324.4572.0%
3 Years20.0074.4811.6346.10693,22538.41192.05%
5 Years15.0074.4811.6345.72647,61443.41289.4%

CRISPR Therapeutics Description

CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.